📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Entero Healthcare Q3 FY26: Revenue Up 26% YoY to ₹1,707 Cr, EBITDA Margins Expand to 4%
Entero Healthcare reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,707 crores, driven by 17.1% organic growth. EBITDA margins expanded by 30 bps to 4%, while adjusted PAT rose 36% to ₹40 crores after accounting for a one-time labor code impact. The company successfully closed several MedTech acquisitions, projecting this segment's annualized revenue to exceed ₹1,000 crores. Management remains confident in achieving its ₹100 crore operating cash flow target for FY26.
Key Highlights
Revenue grew 26% YoY to ₹1,707 crores with a record 17.1% organic growth rate.
EBITDA increased 36% YoY to ₹68 crores, achieving a 4% margin.
MedTech acquisitions completed; segment revenue expected to surpass ₹1,000 crores with 50-75 bps EBITDA margin accretion.
Net Working Capital improved to 61 days (like-to-like), generating ₹49 crores in operating cash flow this quarter.
Adjusted PAT grew 36% YoY to ₹40 crores, excluding a ₹6.1 crore one-off labor code impact.
💼 Action for Investors
Investors should monitor the integration of recent MedTech acquisitions and the company's ability to meet its ₹100 crore operating cash flow guidance in Q4. The shift towards higher-margin MedTech and improved working capital efficiency are positive long-term indicators.
Entero Healthcare Q3 FY26 Revenue at ₹1,067M; PAT Impacted by ₹44.8M Exceptional Item
Entero Healthcare reported a revenue of ₹1,067.35 million for the quarter ended December 31, 2025, showing growth over the previous quarter's ₹832.21 million. Net profit for the quarter stood at ₹8.05 million, significantly impacted by a one-time exceptional charge of ₹44.87 million related to the implementation of New Labour Codes. The company has successfully utilized its total IPO proceeds of ₹5,548 million for debt repayment, working capital, and inorganic growth. Multiple acquisitions were completed during the period, including Ramson Medical and Sri RK Pharma, to strengthen its distribution network.
Key Highlights
Revenue from operations grew to ₹1,067.35 million in Q3 FY26 compared to ₹832.21 million in Q2 FY26.
Profit After Tax (PAT) for Q3 FY26 was ₹8.05 million, following a ₹44.87 million exceptional item for labor code compliance.
The company fully utilized ₹5,548 million of IPO proceeds, with ₹1,425 million used for debt repayment.
Aggressive inorganic expansion continued with the acquisition of six entities including Ramson Medical and Bio-side Technologies.
9M FY26 PAT stood at ₹134.59 million on a total income of ₹3,430.76 million.
💼 Action for Investors
Investors should monitor the integration of recent acquisitions and the impact on margins once one-time labor code costs are absorbed. The revenue growth trend is positive, but bottom-line consistency is key for long-term valuation.
Entero Healthcare Q3 Standalone PAT Drops to ₹8.06M; Cancels Two Acquisitions
Entero Healthcare reported a standalone revenue of ₹1,067.36 million for Q3 FY26, showing growth from ₹832.21 million in the previous quarter. However, Standalone Profit After Tax (PAT) plummeted to ₹8.06 million from ₹107.83 million in the same quarter last year, a significant year-on-year decline. This drop was exacerbated by a ₹44.97 million exceptional item related to incremental liabilities from New Labour Codes. Additionally, the company cancelled the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons.
Key Highlights
Standalone Revenue from operations stood at ₹1,067.36 million for Q3 FY26 compared to ₹1,011.52 million YoY.
Net Profit (PAT) fell sharply to ₹8.06 million from ₹107.83 million in the corresponding quarter of the previous year.
Recognized an exceptional expense of ₹44.97 million (₹33.65 million net of tax) due to New Labour Code compliance.
Cancelled two planned acquisitions (Khera Medisolutions and AV Medisolutions) previously announced in 2025.
Board approved the grant of 5,000 fresh Employee Stock Options (ESOPs) under the 2023 plan.
💼 Action for Investors
Investors should monitor the company's ability to maintain margins following the sharp decline in profitability and the impact of regulatory labor costs. The cancellation of two acquisitions may signal a more selective approach to inorganic growth or potential valuation hurdles.
Entero Healthcare Q3 Revenue Up 25.6% to ₹1,707 Cr; Achieves Positive Operating Cash Flow
Entero Healthcare reported a strong Q3FY26 with revenue growing 25.6% YoY to ₹1,706.5 crore, driven by 17.1% organic like-for-like growth. The company achieved a significant milestone by generating positive operating cash flow of ₹49 crore during the quarter, reversing previous negative trends. EBITDA margins improved by 29 bps to 4.0%, while adjusted PAT (excluding a one-off labor code impact) rose 36% to ₹40 crore. Management is aggressively expanding into the high-margin MedTech segment, which is projected to exceed ₹1,000 crore in revenue next fiscal year.
Key Highlights
Reported revenue grew 25.6% YoY to ₹1,706.5 Cr, with organic LFL growth outperforming the industry at 17.1%.
EBITDA increased by 35.5% YoY to ₹67.8 Cr, with margins expanding to 4.0% from 3.7% YoY.
Generated positive Operating Cash Flow of ₹49 Cr in Q3, a sharp turnaround from negative ₹10.3 Cr in Q2FY26.
Completed 7 acquisitions year-to-date, with a strategic focus on the MedTech segment to drive margin expansion.
Net Working Capital (NWC) days improved to 61 on a like-for-like basis compared to 63 in the previous quarter.
💼 Action for Investors
Investors should take note of the company's successful transition to positive operating cash flow and its margin-accretive acquisition strategy in the MedTech space. The stock remains an attractive growth play as it continues to gain market share and consolidate the fragmented healthcare distribution industry.
Entero Healthcare Q3 PAT Drops to ₹8.06M; Cancels Two Acquisitions & Grants 5,000 ESOPs
Entero Healthcare reported a sharp decline in standalone net profit to ₹8.06 million for Q3 FY26, down from ₹107.83 million YoY, largely due to a ₹44.97 million exceptional charge for new labour code compliance. Revenue from operations grew modestly to ₹1,067.36 million from ₹1,011.52 million in the year-ago period. Notably, the company has cancelled the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. The board also approved a small grant of 5,000 fresh ESOPs to employees.
Key Highlights
Standalone Net Profit fell over 92% YoY to ₹8.06 million in Q3 FY26.
Recognized a one-time exceptional expense of ₹44.97 million related to New Labour Code liabilities.
Cancelled two previously announced acquisitions (Khera Medisolutions and AV Medisolutions) citing commercial reasons.
Standalone Revenue from operations increased by 5.5% YoY to ₹1,067.36 million.
Board approved the grant of 5,000 fresh Employee Stock Options under the 2023 Plan.
💼 Action for Investors
Investors should exercise caution as the significant drop in profitability and the cancellation of planned acquisitions suggest potential headwinds in growth and margins. Monitor management's outlook on inorganic growth strategy and the impact of rising employee benefit costs.
Entero Healthcare Approves Q3 Results, Cancels Two Acquisitions, and Grants 5,000 ESOPs
Entero Healthcare Solutions approved its Q3 and nine-month financial results for the period ending December 31, 2025. In a significant strategic shift, the company announced the cancellation of the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. Additionally, the board approved the grant of 5,000 ESOPs to employees at an exercise price of INR 804 per share. The company noted a temporary technical delay in generating the UDIN for the consolidated financial results due to portal maintenance.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Cancelled the acquisitions of Khera Medisolutions and AV Medisolutions, previously announced in 2025.
Granted 5,000 ESOPs under the Entero Employee Stock Option Plan 2023 at an exercise price of INR 804.
ESOPs have a vesting period ranging from 1 to 4 years and an exercise period of 8 years from vesting.
Statutory auditors reported a technical error in UDIN generation for consolidated results, to be updated later.
💼 Action for Investors
Investors should review the detailed Q3 financial performance and seek management commentary regarding the cancellation of the two acquisitions to understand the impact on the company's inorganic growth strategy.
Entero Healthcare Q3 Results Approved; Cancels Two Acquisitions; Grants 5,000 ESOPs
Entero Healthcare's board approved the financial results for the quarter and nine months ended December 31, 2025. A significant strategic update includes the cancellation of the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons. The board also approved the grant of 5,000 ESOPs to eligible employees at an exercise price of INR 804 per share. Additionally, the company noted a technical delay in generating the UDIN for consolidated results due to auditor portal maintenance.
Key Highlights
Approved standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
Cancelled the proposed acquisitions of Khera Medisolutions Private Limited and AV Medisolutions Private Limited.
Granted 5,000 Employee Stock Options (ESOPs) at an exercise price of INR 804 per share.
ESOPs have a vesting period of 1 to 4 years and an exercise period of 8 years from vesting.
Statutory auditors reported a temporary technical error in generating UDIN for consolidated results.
💼 Action for Investors
Investors should closely examine the Q3 financial performance and seek management commentary regarding the 'commercial reasons' for cancelling the two previously announced acquisitions. Monitor the stock's reaction to the INR 804 ESOP exercise price relative to the current market price.
Entero Healthcare Completes 51.5% Stake Acquisition in Anand Chemiceutics
Entero Healthcare has successfully closed the acquisition of a 51.5% stake in Anand Chemiceutics, a prominent diagnostic and MedTech solutions provider. This acquisition significantly expands Entero's footprint in the diagnostic distribution space, adding a network of over 1,500 laboratories and hospitals. Management expects the MedTech segment to contribute more than INR 1,000 crore in annualized revenue during the next financial year. This move is a strategic step toward building an integrated healthcare supply chain platform in India.
Key Highlights
Acquired a 51.5% majority stake in Anand Chemiceutics, a diagnostic and MedTech specialist established in 2003.
The acquisition adds a customer service network of 1,500+ laboratories, hospitals, and government institutions.
MedTech segment is projected to generate over INR 1,000 crore in annualized revenue in the next financial year.
Expands capabilities into high-growth areas like advanced genomics and turnkey solutions for hospitals.
The deal leverages Entero's proprietary technology platform and distribution reach to scale the acquired business.
💼 Action for Investors
Investors should monitor the integration of Anand Chemiceutics as it provides a significant revenue boost and entry into higher-margin diagnostic segments. The projected INR 1,000 crore revenue contribution makes this a key growth driver for the next fiscal year.
Entero Healthcare Completes Acquisition of 51.51% Stake in Anand Chemiceutics
Entero Healthcare Solutions Limited has successfully completed the acquisition of a 51.51% majority equity stake in Anand Chemiceutics Private Limited. This follows the initial announcement made on November 12, 2025, regarding the proposed transaction. The completion of this acquisition allows Entero to consolidate the financials of Anand Chemiceutics, supporting its inorganic growth strategy. This move strengthens the company's position in the healthcare distribution market.
Key Highlights
Acquired a majority equity stake of 51.51% in Anand Chemiceutics Private Limited.
The acquisition process was completed on February 07, 2026.
The transaction was previously disclosed on November 12, 2025.
The move aligns with SEBI Regulation 30 for material disclosures.
💼 Action for Investors
Investors should monitor the upcoming quarterly results to evaluate the margin profile and revenue contribution of the newly acquired entity.